文献速递炎症性肠病

IBD患者使用英夫利西单抗或阿达木单抗的结核风险取决于当地结核病负担:系统综述与荟萃分析

Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis.
PubMed 文献 · Am J Gastroenterol · 2020-01-01

该系统综述与荟萃分析纳入截至2019年1月31日的128项研究、共130114例使用英夫利西单抗(IFX)或阿达木单抗(ADA)的炎症性肠病(IBD)患者,其中373例发生结核,合并患病率为0.08%(95%CI:0.05%-0.10%)。结核风险随当地结核病负担升高而增加,低、中、高负担国家的合并患病率分别为0.02%(95%CI:0.02%-0.03%)、0.21%(95%CI:-0.02%至0.43%)和1.59%(95%CI:1.19%-2.00%)。73%的发生结核患者筛查时无潜伏结核证据,且该比例与结核负担无关;疾病类型、治疗类型、研究类型、性别、IFX/ADA启动年龄及随访时间均不影响结核患病率。

要点

  • IBD患者使用IFX/ADA的结核风险与当地结核病负担相关,高负担国家合并患病率达1.59%。
  • 73%的发生结核患者筛查时无潜伏结核证据,且该比例与结核负担无关。
  • 疾病类型、治疗类型、性别、启动年龄及随访时间不影响结核患病率。

核心结论

  • IBD患者使用IFX/ADA的结核风险取决于当地结核病负担,且与疾病类型或治疗类型无关。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed和Embase截至2019年1月31日的研究,纳入128项研究、共130114例使用IFX/ADA的IBD患者。
  • 从世界卫生组织数据库获取当地结核发病率,将研究按结核负担分层:低(<10/100,000)、中(10-40/100,000)、高(>40/100,000)。
  • 采用随机效应荟萃分析计算总体合并患病率及基于当地结核负担的患病率。

主要发现

  • 130114例患者中373例发生结核,总体合并患病率为0.08%(95%CI:0.05%-0.10%)。
  • 低结核负担国家合并患病率为0.02%(95%CI:0.02%-0.03%),中等负担国家为0.21%(95%CI:-0.02%至0.43%),高负担国家为1.59%(95%CI:1.19%-2.00%)。
  • 73%的发生结核患者筛查时无潜伏结核证据,该比例与结核负担无关。
  • 疾病类型、治疗类型、研究类型、性别、IFX/ADA启动年龄及随访时间对结核患病率无影响。

关键数值与推荐

  • 结核负担分层标准:低<10/100,000,中10-40/100,000,高>40/100,000。
  • 总体合并结核患病率0.08%(95%CI:0.05%-0.10%)。
  • 低负担国家合并患病率0.02%(95%CI:0.02%-0.03%),中等负担国家0.21%(95%CI:-0.02%至0.43%),高负担国家1.59%(95%CI:1.19%-2.00%)。
  • 73%的发生结核患者筛查时无潜伏结核证据。

临床怎么用

  • 对使用IFX/ADA的IBD患者,应结合当地结核病负担评估结核风险,高负担地区需加强监测。
  • 即使筛查时无潜伏结核证据,仍需警惕结核发生,因73%的发生结核患者筛查时无潜伏结核证据。
  • 疾病类型和治疗类型不影响结核风险,不应据此调整结核预防策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Infliximab (IFX) or adalimumab (ADA) use in patients with inflammatory bowel disease (IBD) leads to increased risk of tuberculosis (TB). This meta-analysis evaluated the factors which determine this risk, with special focus on local TB incidence. METHODS: All studies until January 31, 2019, which reported the development of TB in patients with IBD on IFX/ADA, were included after searching PubMed and Embase. Data regarding disease type, number of patients on IFX/ADA, number of patients who developed TB, mean age at IFX/ADA initiation, median duration of development of TB, and latent TB (LTB) were extracted. The details on local TB incidence were obtained from the World Health Organization database, and the studies were stratified into low (<10/100,000), intermediate (10-40/100,000), and high TB burden countries (>40/100,000). Random effect meta-analysis was performed to calculate the overall pooled prevalence and prevalence based on local TB burden. RESULTS: Of 130,114 patients (128 studies), 373 developed TB (pooled prevalence: 0.08% [95% confidence interval {CI}: 0.05%-0.10%]). The risk increased with increasing TB burden, pooled prevalence being 0.02% (95% CI: 0.02%-0.03%), 0.21% (95% CI: -0.02% to 0.43%), and 1.59% (95% CI: 1.19%-2.00%) for low, intermediate, and high TB burden countries, respectively. Seventy-three percent of patients who developed TB had no evidence of LTB on screening, the proportion being independent of TB burden. There was no effect of disease or treatment type, study type, gender, age at IFX/ADA initiation, and follow-up duration on TB prevalence. DISCUSSION: TB risk in patients with IBD on IFX/ADA depends on the local TB burden and is independent of disease/treatment type.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Kedia S, Mouli VP, Kamat N, et al. Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2020. PMID: 32032073. doi:10.14309/ajg.0000000000000527

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。